Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males
Phase of Trial: Phase I
Latest Information Update: 25 Dec 2016
At a glance
- Drugs ODM 106 (Primary)
- Indications Essential tremor
- Focus Adverse reactions
- Acronyms FIMPAM
- Sponsors Orion
- 02 Feb 2016 According to an Orion media release, status changed from recruiting to discontinued.
- 14 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.
- 14 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.